Clinical trials in the Cayman Islands: no phase 1, no paying patients

The Cayman Islands has positioned itself as a medical-tourism destination, and the Health Practice Act allows Cabinet to designate medical tourism providers and facilities by order (section 7A)³. Research is a different matter. On 9 January 2026 the Health Practice Commission published "Appraisal of Clinical Trial Applications in the Cayman Islands", a nine-page standard that tells applicants, in plain terms, how hard it will be to get a trial approved¹². For physicians interested in peptides, regenerative medicine or any therapy still under study, it is now the key document.

The legal basis: section 9 of the Health Practice Act

Under section 9 of the Health Practice Act (2026 Revision), the manager of a health care facility "shall not permit any person to carry out clinical trials in a health care facility without the prior written consent of the Commission"; a manager who does commits an offence punishable by a fine of ten thousand dollars³. The new guidance opens by restating that clinical practitioners "may undertake research only with the explicit permission of the Health Practice Commission" and that granting it "is not trivial" because, by definition, the treatment under study lacks well-established safety or outcome data¹.

What the Commission will require

The Commission is candid about its limits: "the Cayman Islands does not have an established clinical research oversight infrastructure" nor a well-resourced academic community, yet the law does not allow it to refuse applications simply for lack of resources¹. Its answer is a set of objective tests, adapted from UK practice and the National Institute for Health and Care Research toolkit¹:

• Phase restrictions. Phase 1 trials are ruled out; phase 2 trials "ordinarily may not be permitted" without exceptional phase 1 safety evidence; phase 3 and 4 trials are "more likely to be acceptable"¹.
• Evidence first. No trial proceeds without an unbiased review of peer-reviewed literature and prior phase 1/2 evidence of effect, and evidence of benefit or non-inferiority and tolerable side effects should come from a prior phase 2/3 trial. Presenting that evidence is the researchers' job, "not the HPC or CIG officials"¹.
• Design. Defined endpoints, a power calculation, preferably control groups, statistician oversight and rules for stopping early¹.
• Consent and exclusions. Written informed consent, the right to withdraw at no cost, and, ordinarily, no trials in people who lack capacity, children under 16, pregnant women or prisoners¹.
• People and conflicts. A named chief investigator and data controller, a team trained in Good Clinical Practice, documented back-up from other clinical providers, and a declaration of conflicts of interest, including industry sponsorship¹.
• Money. "Participants must not be charged, in any manner or under any pretext, for their participation in a clinical trial, irrespective of the trial's outcome"¹.
• Reporting. Immediate notification, defined as within 24 hours, of any significant event, unexpected side-effect or breach of Good Clinical Practice or protocol to the Commission and the Chief Medical Officer; a final report with all adverse events; and publication of results, including negative ones¹.

The default is refusal. If reviewers cannot satisfy themselves of the benefit, utility or safety of a trial, "they must, by default, refuse to issue a positive recommendation", and a permission is "a privilege that should only exceptionally be allowed, and not a right that can be demanded"¹.

Why it matters for peptides and regenerative medicine

Many products discussed as "peptides" have exactly the evidence profile the Commission says it cannot approve. A 2025 systematic review of BPC-157 found 36 studies, 35 of them preclinical and one clinical, and no clinical safety data⁶. In July 2026 the US FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides for the 503A bulks list used in compounding, BPC-157 among them⁷, but that is a compounding decision, not trial evidence. By contrast, the phase 3 programs behind GLP-1 drugs enrolled thousands of patients (17,604 in SELECT, 2,539 in SURMOUNT-1), the kind of base the Cayman standard expects before a trial in humans¹¹¹².

The ban on charging participants targets a familiar problem in regenerative medicine: patients paying to receive unproven treatments under a research label. Reviews of unproven stem cell interventions have catalogued reported safety incidents⁹, and stem cell scientists have argued that first-in-human trials raise particular challenges for ethics boards¹⁰. Outside formal trials, events like the 2025 RAADfest case in Las Vegas, where two women needed breathing tubes after peptide injections and investigators could not obtain the product, show how little can be learned when nothing is protocolized⁸.

What physicians in the Cayman Islands should do

Any study that tests a medicine or procedure on patients inside a facility needs the Commission's written consent before it starts³. Applicants should expect to bring phase 2/3 evidence, insurance cover, a statistician and a Good Clinical Practice-trained team, and should not plan cost recovery from participants¹. The Health Practice (Amendment) Bill, 2026, passed by Parliament in April 2026, adds another layer: it lets Cabinet set professional standards, including on "clinical trials and research", that apply to every registered healthcare practitioner⁴, and the government's consultation stressed stronger safeguards in areas such as consent¹³. Current practitioner and facility lists are published by the Department of Health Regulatory Services⁵.